Business Description
Inozyme Pharma Inc
NAICS : 541714
SIC : 2834
ISIN : US45790W1080
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 4.05 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.33 | |||||
Debt-to-EBITDA | -0.7 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 36.9 | |||||
3-Year EPS without NRI Growth Rate | 35.5 | |||||
3-Year FCF Growth Rate | 25.5 | |||||
3-Year Book Growth Rate | -30.5 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 78.7 | |||||
9-Day RSI | 54.11 | |||||
14-Day RSI | 46.34 | |||||
6-1 Month Momentum % | 114.38 | |||||
12-1 Month Momentum % | 8.83 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 13.36 | |||||
Quick Ratio | 13.36 | |||||
Cash Ratio | 12.84 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -38.2 | |||||
Shareholder Yield % | -10.37 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -56.66 | |||||
ROA % | -42.44 | |||||
ROIC % | -1034.9 | |||||
ROC (Joel Greenblatt) % | -2157.22 | |||||
ROCE % | -43.93 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.15 | |||||
Price-to-Tangible-Book | 2.15 | |||||
EV-to-EBIT | -2.23 | |||||
EV-to-EBITDA | -2.26 | |||||
EV-to-FCF | -2.13 | |||||
Price-to-Net-Current-Asset-Value | 2.22 | |||||
Price-to-Net-Cash | 2.35 | |||||
Earnings Yield (Greenblatt) % | -44.84 | |||||
FCF Yield % | -23.51 |